Novus Therapeutics (NASDAQ:NVUS) vs. Vertex Pharmaceuticals (NASDAQ:VRTX) Financial Contrast

Novus Therapeutics (NASDAQ:NVUS) and Vertex Pharmaceuticals (NASDAQ:VRTX) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, dividends, analyst recommendations, institutional ownership, earnings, risk and profitability.

Institutional and Insider Ownership

28.9% of Novus Therapeutics shares are held by institutional investors. Comparatively, 94.0% of Vertex Pharmaceuticals shares are held by institutional investors. 5.7% of Novus Therapeutics shares are held by company insiders. Comparatively, 0.7% of Vertex Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.



Risk & Volatility

Novus Therapeutics has a beta of 2.87, meaning that its share price is 187% more volatile than the S&P 500. Comparatively, Vertex Pharmaceuticals has a beta of 1.4, meaning that its share price is 40% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Novus Therapeutics and Vertex Pharmaceuticals, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Novus Therapeutics 0 0 1 0 3.00
Vertex Pharmaceuticals 0 8 14 0 2.64

Novus Therapeutics currently has a consensus target price of $10.00, indicating a potential upside of 1,198.70%. Vertex Pharmaceuticals has a consensus target price of $207.79, indicating a potential upside of 13.10%. Given Novus Therapeutics’ stronger consensus rating and higher probable upside, equities analysts clearly believe Novus Therapeutics is more favorable than Vertex Pharmaceuticals.

Profitability

This table compares Novus Therapeutics and Vertex Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Novus Therapeutics N/A -116.18% -99.51%
Vertex Pharmaceuticals 64.13% 21.73% 15.26%

Valuation and Earnings

This table compares Novus Therapeutics and Vertex Pharmaceuticals’ revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Novus Therapeutics N/A N/A -$14.06 million ($1.56) -0.49
Vertex Pharmaceuticals $3.05 billion 15.49 $2.10 billion $2.83 64.92

Vertex Pharmaceuticals has higher revenue and earnings than Novus Therapeutics. Novus Therapeutics is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Vertex Pharmaceuticals beats Novus Therapeutics on 9 of the 13 factors compared between the two stocks.

Novus Therapeutics Company Profile

Novus Therapeutics, Inc., a pharmaceutical company, focuses on developing products for patients with disorders of ear, nose, and throat. Its lead product is (OP-02), a surfactant-based combination drug product for patients at risk for, or with, otitis media (OM) (middle ear inflammation with or without infection). The company also has a foam-based drug delivery technology (OP-01) that could be used to deliver drugs into the ear, nose, and sinus cavities. Novus Therapeutics, Inc. is headquartered in Irvine, California.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene. It is also developing VX-659 and VX-445 that are Phase III clinical trials; VX-121, a cystic fibrosis transmembrane conductance regulator corrector that is in Phase I/II clinical trial; VX-150, an inhibitor that is in Phase IIb clinical trial for acute pain; CTX001 that is in Phase I/II clinical trial for the treatment of beta-thalassemia and sickle cell diseases; and a novel drug candidate, which is in Phase I clinical trial for the treatment for alpha-1 antitrypsin deficiency. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. Vertex Pharmaceuticals Incorporated has collaborations with CRISPR Therapeutics AG; Arbor Biotechnologies, Inc.; Moderna Therapeutics, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany; X-Chem, Inc.; Janssen Pharmaceuticals, Inc.; Merck KGaA; and Kymera Therapeutics. The company was founded in 1989 and is headquartered in Boston, Massachusetts.

Receive News & Ratings for Novus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.